Why a 25-cent pill is being sold to cancer patients for nearly $1,000

Sobre este episódio

<p>When <em>ProPublica</em> health-care reporter David Armstrong was diagnosed with a rare blood cancer, he began taking a lifesaving drug called Revlimid. When he learned that each pill of this medication is sold for nearly $1,000 but costs drug companies only cents to make, he went on a quest to uncover the reasons behind its shocking price tag. Armstrong sat down with <em>Apple News In Conversation</em> host Shumita Basu to talk about his <a href="https://apple.news/ATKPlgJFmSV6qNJCo0bjbVA" target="_blank" rel="noopener noreferrer">investigation</a> into Revlimid&rsquo;s origins and what it reveals about prescription-drug pricing in America.</p>